title: Impact of human amniotic membrane preparation on release of angiogenic factors.
abstract: Preserved amniotic membrane (AM) has been used in the field of ophthalmology and wound care due to its bacteriostatic, antiphlogistic, protease-inhibiting, re-epithelialization, wound-protecting and scar formation-reducing properties. Typically, AM is applied after banking in a glycerol-preserved or freeze-dried state. Cell viabilities in different forms of preparation vary substantially, which in consequence may also be reflected in the amount and type of growth factors released from the preserved material. Therefore, we characterized the angiogenic factor (AF) profile released from different AM preparations. For this, medium was conditioned with non-preserved, glycerol- and cryo-preserved AM for 48 h, which was screened for AFs using a protein array system. In parallel, the preparations were tested for cell viability. Non-preserved as well as cryo-preserved AM maintained viabilities at 106.5 +/- 23.9% and 21.9 +/- 23.3%, respectively, whereas glycerol-preserved AM was found to be non-viable. Of the 20 investigated factors, high levels of angiogenin, GRO, IL-6/8, TIMP-1/2 and MCP-1 and low levels of EGF, IFNgamma, IGF-1, leptin, RANTES, TGFbeta1 and thrombopoietin were identified to be secreted from non-preserved AM. Cryo-preserved AM secreted high levels of IL-8, intermediate levels of GRO and TIMP-1/2 but only low levels of angiogenin, IFNgamma, IL-6 and MCP-1 and no detectable EGF, IGF-1, leptin, RANTES, TGFbeta1 and thrombopoietin. After banking in glycerol, AM releases only minute amounts of TIMP-1/2. Along with viability, the AF profile of amniotic membrane largely depends on the preparation method applied for banking. This should be considered for selection of an AM product for a specific clinical application.
authors.affiliation: Ludwig Boltzmann Institute for Experimental and Clinical Traumatology/AUVA Research Centre, Linz/Vienna, Austria.
authors.forename: S
authors.initials: S
authors.lastname: Wolbank
authors.forename: F
authors.initials: F
authors.lastname: Hildner
authors.forename: H
authors.initials: H
authors.lastname: Redl
authors.forename: M
authors.initials: M
authors.lastname: van Griensven
authors.forename: C
authors.initials: C
authors.lastname: Gabriel
authors.forename: S
authors.initials: S
authors.lastname: Hennerbichler
mesh_terms: D000650:Amnion / Q000378:metabolism*; D043925:Angiogenesis Inducing Agents / Q000378:metabolism*; D002470:Cell Survival; D015925:Cryopreservation; D017077:Culture Media, Conditioned / Q000378:metabolism; D005786:Gene Expression Regulation; D005990:Glycerol / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D040081:Protein Array Analysis; D013997:Time Factors; D023822:Tissue Engineering / Q000379:methods; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000378:metabolism; D014945:Wound Healing
chemical_list: D043925:Angiogenesis Inducing Agents; D017077:Culture Media, Conditioned; D019715:Tissue Inhibitor of Metalloproteinase-1; D019716:Tissue Inhibitor of Metalloproteinase-2; D005990:Glycerol